2024-12-25 - Analysis Report
## Eli Lilly and Co (LLY) Stock Report

**1. Performance Comparison and Divergence:**

Eli Lilly and Co (LLY), a leading pharmaceutical company, has significantly outperformed the S&P 500 (VOO) over the given period.  The cumulative return for LLY is 579.80%, while VOO's is 117.56%.  The difference in cumulative returns is 462.24%, placing it at the 73.9th percentile of its historical range of divergence (max: 634.7%, min: -25.2%).  This indicates a substantial outperformance relative to the broader market.  The provided Alpha values of 0.0 suggest that the outperformance is not solely attributable to systematic market risk (Beta), but rather to company-specific factors.

**2. Recent Price Movement:**

* **Closing Price:** $796.28
* **Last Market Price:** $795.67
* **5-Day Moving Average:** $772.98
* **20-Day Moving Average:** $791.89
* **60-Day Moving Average:** $832.66

The price is slightly below the 20-day moving average and considerably below the 60-day moving average, suggesting a recent downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 44.05 – This suggests the stock is approaching oversold territory, potentially indicating a bounce back.
* **PPO:** 0.03 – A positive value, indicating bullish momentum, although relatively weak.
* **20-Day Relative Divergence:** +2.9 – This signifies a recent short-term upward trend.
* **Expected Return:** 549.5% –  This represents a substantial long-term (2+ years) outperformance relative to the S&P 500, assuming the current trend continues. However, this is a high projection and should be considered with caution.  A price of $795.67 doesn't indicate a significant immediate jump (neither a rapid surge nor a sharp drop) based on the provided data.


**4. Recent Earnings Analysis:**

The provided earnings data shows significant volatility.

* **Revenue:** Revenue has fluctuated between $8.77B and $11.44B over the past four quarters, with no clear consistent upward trend.
* **EPS:** EPS has been highly volatile, ranging from -$0.06 to $3.29. This highlights significant quarter-to-quarter variation, potentially due to various factors, including seasonal effects and one-time items not reflected in the provided data.  There is no consistent trend.  No information is provided to evaluate whether these figures beat or missed expectations.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue shows some fluctuation but generally remains strong. Profit margins are consistently high, ranging from 80.42% to 81.02%, indicating strong profitability.
* **Capital and Profitability:** Equity has shown growth, but the Return on Equity (ROE) is highly variable, suggesting potential fluctuations in profitability and possibly significant investment activity. The negative ROE in 2023-09-30 is a notable point requiring further investigation beyond the provided data.


**6. News and Recent Issues:**

No information on recent earnings news (within the last two days), market outlook, or analyst opinions is provided. This is crucial missing context for a complete analysis.


**7. Overall Analysis:**

LLY has significantly outperformed the S&P 500 over the provided timeframe. However,  recent price action suggests a potential short-term downward trend. While the company shows strong profitability, the highly variable EPS and ROE raise concerns about consistency.  The provided financial data lacks crucial context, like comparisons to expectations, making a comprehensive evaluation challenging. The significant predicted long-term outperformance should be treated with considerable skepticism due to the volatility shown in the available data and the lack of context about market outlook and analyst sentiment.  More information, especially regarding recent news and earnings expectations, is needed for a robust analysis.


**8. Recommendations:**

Given the limited data and the inherent volatility in the pharmaceutical sector, it's premature to offer definitive investment recommendations.  Further research is needed to assess the company's current position within the broader market and the sustainability of its past exceptional performance. A thorough review of recent news, analyst reports, and a more comprehensive set of financial statements would enable a more informed and accurate assessment of LLY's investment potential.
